# A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

> **NCT02272634** · PHASE2 · COMPLETED · sponsor: **Yungjin Pharm. Co., Ltd.** · enrollment: 61 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** YPL-001 80 mg
- **DRUG:** YPL-001 160 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02272634
- **Lead sponsor:** Yungjin Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-04
- **Primary completion:** 2017-11-08
- **Final completion:** 2017-11-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02272634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02272634, "A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02272634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*